logo
Plus   Neg
Share
Email

Plaque Psoriasis Armamentarium Gets New Addition

skyrizi-april24-lt.jpg

The therapeutic armamentarium for plaque psoriasis patients is fairly well-stocked, and now there is one more addition to it.

The FDA has approved AbbVie's (ABBV) Skyrizi for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

What is plaque psoriasis?

More than 8 million Americans have psoriasis, according to the National Psoriasis Foundation.

Plaque psoriasis is the most common form of psoriasis, and it appears as raised, red patches covered with a silvery white buildup of dead skin cells or scale.

Topical treatments with and without steroids, phototherapy, systemic medications (the ones taken by mouth in liquid or pill form or given by injection) are the treatments for plaque psoriasis.

Some of the latest FDA approvals for plaque psoriasis are Bausch Health Companies Inc.'s (BHC) Bryhali Lotion 0.01%, which was green-lighted last November, Novartis' Hyrimoz, administered by subcutaneous injection, approved in October of 2018, and Sun Pharma's Ilumya, also administered by subcutaneous injection, approved last March.

Skyrizi - Recommended Dose and Availability

The recommended dose for Skyrizi is 150mg - administered by two subcutaneous injections every 12 weeks following two initiation doses at week 0 and 4. The drug is expected to be available in the U.S. in early May of this year.

Skyrizi, whose generic name is Risankizumab-rzaa, is developed by AbbVie in collaboration with Boehringer Ingelheim.

In February of this year, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval of Skyrizi, and a final decision is expected in the first half of this year.

Analysts expect Skyrizi to bring in global sales of $2.3 billion.

ABBV closed Tuesday's trading at $78.66, up 0.65%.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT